Table 2.

Age-specific incidence of hrHPV, (non-)bivalent vaccine types and (non-)polyvalent vaccine types

AgeAt riskhrHPVBivalent vaccine typesaNonbivalent vaccine typesbPolyvalent vaccine typescNonpolyvalent vaccine typesd
Nn% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)
POBASCAM
29–331,8991085.69 (4.69–6.83)442.32 (1.67–3.10)774.05 (3.22–5.04)884.63 (3.73–5.68)341.79 (1.24–2.49)
34–383,6711253.41 (2.84–4.04)481.31 (0.97–1.73)892.42 (1.95 -2.98)942.56 (2.07–3.12)451.23 (0.90–1.64)
39–433,251682.09 (1.63–2.64)250.77 (0.50–1.13)471.46 (1.06–1.92)471.45 (1.06–1.92)240.74 (0.48–1.10)
44–483,174561.76 (1.34–2.29)130.41 (0.22–0.70)451.42 (1.04–1.89)341.07 (0.74–1.49)240.76 (0.49–1.12)
49–532,639451.71 (1.25–2.28)160.61 (0.35–9.83)301.14 (0.77–1.62)311.17 (0.80–1.66)150.57 (0.32–0.94)
54–562,037211.03 (0.64–1.57)80.39 (0.17–0.77)130.64 (0.34–1.09)160.79 (0.45–1.27)50.25 (0.08–0.57)
Total16,6714232.54 (2.30–2.78)1540.92 (0.78–1.08)3011.81 (1.61–2.02)3101.86 (1.66–2.08)1470.88 (0.75–1.04)
Linear effect: regression coefficient (SE)e−0.066 (0.007)h−0.079 (0.012)h−0.068 (0.008)h−0.076 (0.008)h−0.063 (0.012)h
Nonlinear effect: regression coefficient (SE)f0.002 (<0.001)i0.003 (0.001)i0.001 (0.001)0.003 (0.001)i<0.001 (0.002)
NTCC
24–28748658.69 (6.77–10.94)263.48 (2.28–5.05)476.28 (4.65–8.27)466.15 (4.54–8.12)283.74 (2.5–5.36)
29–33961535.52 (4.16–7.15)282.91 (1.94–4.18)323.33 (2.29–4.67)444.58 (3.35–6.1; 44)151.56 (0.88–2.56)
34–381222403.27 (2.35–4.43)100.82 (0.39–1.5)232.62 (1.8–3.68)272.21 (1.46–3.2; 27)181.47 (0.88–2.32)
39–431123292.58 (1.74–3.69)100.89 (0.43–1.63)232.05 (1.3–3.06)151.34 (0.75–2.19; 15)151.34 (0.75–2.19)
44–481112242.16 (1.39–3.19)80.72 (0.31–1.41)181.62 (0.96–2.55)121.08 (0.56–1.88; 12)121.08 (0.56–1.88)
49–53901121.33 (0.69–2.31)40.44 (0.12–1.13)101.11 (0.53–2.03)80.89 (0.38–1.74; 8)40.44 (0.12–1.13)
54–5666781.2 (0.52–2.35)40.6 (0.16–1.53)60.9 (0.33–1.95)71.05 (0.42–2.15; 7)30.45 (0.09–1.31)
57–6070020.29 (0.03–1.03)00 (0–0.53)20.29 (0.03–1.03)10.14 (0–0.79; 1)10.14 (0–0.79)
Total74342333.13 (2.75–3.56)901.21 (0.97–1.49)1702.29 (1.96–2.65)1602.15 (1.83–2.51; 160)961.29 (1.05–1.57)
Linear effect: regression coefficient (SE)e,g−0.068 (0.011)h−0.083 (0.018)h−0.057 (0.012)h−0.084 (0.014)h−0.049 (0.016)i
Nonlinear effect: regression coefficient (SE)f,g0.001 (0.001)0.005 (0.002)i<0.001 (0.002)0.004 (0.002)i−0.002 (0.002)
  • aBivalent vaccine types includes HPV types 16 and 18.

  • bNonbivalent vaccine types includes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.

  • cPolyvalent vaccine types includes HPV types 16, 18, 31, 33, 45, 52, and 58.

  • dNonpolyvalent vaccine types includes HPV types 35, 39, 51, 56, 59, and 68. The classification in HPV types is not mutually exclusive and totals of bivalent + nonbivalent and polyvalent + nonpolyvalent types exceed the 100% as a result of multiple type infections.

  • eRegression coefficient and standard error of the linear term in logistic regression models, including age as continuous variable.

  • fRegression coefficient and standard error of the nonlinear (quadratic) term in logistic regression models, including age and age squared as continuous variable.

  • gRestricted to the same age range as POBASCAM (29–56 years).

  • hP < 0.001.

  • iP < 0.05.